Klin Farmakol Farm. 2026;40(3):158-163 | DOI: 10.36290/far.2026.026

Current options in insulin therapy

Ondřej Krystyník
III. interní klinika - nefrologická, revmatologická a endokrinologická Lékařské fakulty Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc

Insulin therapy remains a cornerstone of diabetes management despite major advances in non-insulin pharmacotherapy. Its current form is shaped by three interrelated pillars: pharmacological innovation, technological advancement, and individualized care. The development of insulin analogues has improved pharmacokinetic and pharmacodynamic profiles, reducing variability and the risk of hypoglycemia. At the same time, continuous glucose monitoring and automated insulin delivery systems have enabled more precise and safer glycemic control. Individualization of therapy reflects patient heterogeneity and allows treatment to be tailored to clinical characteristics, risks, and lifestyle. Although these advances have substantially improved outcomes, achieving fully physiological glucose regulation remains an ongoing challenge.

Keywords: insulin therapy, insulin analogues, basal insulin, prandial insulin, continuous glucose monitoring, CGM, automated insulin delivery, AID, individualized treatment, diabetes mellitus.

Received: April 29, 2026; Revised: July 1, 2026; Accepted: July 1, 2026; Published: October 14, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krystyník O. Current options in insulin therapy. Klin Farmakol Farm. 2026;40(3):158-163. doi: 10.36290/far.2026.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akbarian M. Insulin therapy: a valuable legacy and its future perspective. Int J Biol Macromol. 2021;181:1224-1230. Go to original source...
    2. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treat­ment: Standards of Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S183.
    3. Kramer CK, Retnakaran R, Zinman B. Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. Cell Metab. 2021;33(4):740-747. Go to original source...
    4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-986. Go to original source...
    5. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358(9283):739-746. Go to original source...
    6. Simoni RD, Hill RL, Vaughan M. The discovery of insulin: the work of Frederick Banting and Charles Best. J Biol Chem. 2002;277(26):e1-e2. Go to original source...
    7. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008;3(1):90-97. Go to original source...
    8. Zaykov AN, Mayer JP, DiMarchi RD. Pursuit of a perfect insulin. Nat Rev Drug Discov. 2016;15(6):425-439. Go to original source...
    9. Kang S, Brange J, Burch A, et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care. 1991;14(11):942-948. Go to original source...
    10. Cheng R, Taleb N, Stainforth-Dubois M, et al. The promising future of insulin therapy in diabetes mellitus. Am J Phy­siol Endocrinol Metab. 2021;320(5):E886-E890. Go to original source...
    11. Howey DC. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402. Go to original source...
    12. Hirsch IB, Juneja R, Beals JM, et al. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(5):733-755. Go to original source...
    13. Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17(7):682-688. Go to original source...
    14. Andersen G, Meiffren G, Lamers D, et al. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab. 2018;20(11):2627-2632. Go to original source...
    15. Hagedorn HC, Jensen BN, Krarup NB, et al. Protamine insulinate. JAMA. 1936;106(3):177-180. Go to original source...
    16. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003;26(5):1490-1496. Go to original source...
    17. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228): 443-445. Go to original source...
    18. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498-1504. Go to original source...
    19. Becker RHA, Dahmen R, Bergmann K, et al. New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care. 2015;38(4):637-643. Go to original source...
    20. Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6(2):e009421. Go to original source...
    21. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191-204. Go to original source...
    22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-long­acting basal insulin, versus insulin glargine in basal-bolus treat­ment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489-1497. Go to original source...
    23. Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. Endocr Rev. 2024;45(3):379-413. Go to original source...
    24. Oleck J, Kassam S, Goldman JD. Commentary: why was inhaled insulin a failure in the market? Diabetes Spectr. 2016;29(3):180-184. Go to original source...
    25. Bakh NA, Bisker G, Lee MA, et al. Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling. Adv Healthc Mater. 2017;6(22):1700601. Go to original source...
    26. Subramanian S, Khan F, Hirsch IB. New advances in type 1 diabetes. BMJ. 2024;384.
    27. Teo E, Hassan N, Tam W, et al. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022;65(4):604-619. Go to original source...
    28. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S150.
    29. Ware J, Hovorka R. Recent advances in closed-loop insulin delivery. Metabolism. 2022;127:154953. Go to original source...
    30. Klonoff DC, Kerr D. Smart pens will improve insulin therapy. J Diabetes Sci Technol. 2018;12(3):551-553. Go to original source...
    31. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S132-S149. Go to original source...
    32. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5): 1520-1574. Go to original source...
    33. Kudva YC, Henderson RJ, Kanapka LG, et al. Automated insulin delivery in older adults with type 1 diabetes. NEJM Evid. 2025;4(1):EVIDoa2400200. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.